Jointly Provided by St. Joseph’s Hospital and Medical Center, MandatoryCE, LLC, and Arizona Pharmacy Association.

 

Developed in collaboration with:

Arizona State Physicians Association

Arizona Academy of Family Physicians

Arizona Latin-American Medical Association

Arizona State Association of Physician Assistants

Arizona LeadingAge

Arizona Diabetes Foundation

Thursday
May182017

SW Diabetes

 

Agenda

7:00am Registration and Breakfast in Exhibit Area
7:55am Welcome and Introduction
8:00am Update on the Epidemiology of Type 2 Diabetes Mellitus (T2DM) in the Southwestern US, Nationwide, and Worldwide
8:15am Update on RAF/HCC Scoring and Reimbursement for Diabetes and Diabetes-Related Services by Medicare and Private Health Insurers
9:15am Strategies to Promote Lifestyle Modification and Behavioral Changes in Patients with T2DM and Prediabetes
10:00am Practical Tools and Clinical Guidelines for Managing Obesity as a Chronic Progressive Disease
10:30am Break and Refreshments in Exhibit Area
11:00am Managing Cardio-Renal-Metabolic Conditions in Patients with T2DM
11:45am Update on 2019 Clinical Practice Guidelines and Evidence-Based Recommendations for Individualized Management and Treatment of Patients with T2DM
1:00pm Q & A, Faculty Panel Discussion
1:30pm Adjourn

 

 

Register today for this complimentary symposium by selecting a date/city from the drop down list below, or call 888-YourCE1 (888-968-7231).

 

Target Audience
This activity is designed for family practice and other primary care physicians, endocrinologists, nurse practitioners, physician assistants, registered nurses, pharmacists, diabetes educators, registered dietitians, and other healthcare professionals who care for patients with type 2 diabetes mellitus (T2DM).

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  1. Identify current statistics and future projections for type 2 diabetes mellitus (T2DM) in Arizona, the southwestern US, nationwide, and worldwide.
  2. Explain CMS’ RAF/HCC point system that adjusts CMS payments and identify current reimbursable diabetes care services to improve quality of care, patient outcomes, and augment comprehensive diabetes management.
  3. Develop lifestyle modification goals based on individual preferences to facilitate behavioral changes in patients with T2DM and prediabetes.
  4. Recognize obesity as a chronic progressive disease and utilize evidence-based management strategies to support weight loss goals in patients with T2DM.
  5. Describe the links between cardiovascular, renal, and metabolic disorders, and the clinical management of these overlapping diseases and potential complications.
  6. Review the updated 2019 AACE/ADA guidelines and apply best practices and evidence-based strategies for the individualized treatment of patients with T2DM.

Activity Goal/Desired Result
Improved clinical performance through increased knowledge and utilization of current evidence-based treatments and guidelines; greater recognition and management of factors that have an impact on the care of patients with type 2 diabetes mellitus (T2DM), including lifestyle modification, behavioral changes, obesity, cardio-renal-metabolic conditions, and reimbursable diabetes-related services.

Summary of Identified Practice Gaps and Educational Needs
In Arizona, diagnosed and undiagnosed type 2 diabetes mellitus (T2DM) has more than doubled in the last 10 years and currently affects approximately 695,000 adults. Of greater concern are the 1,796,000 people in Arizona estimated to have prediabetes; without weight loss and moderate physical activity, 15-30% of this group will develop T2DM within the next five years. The medical cost of people with diabetes is approximately 2.3 times higher than those who do not have diabetes. Statistics from 2017 show that direct medical expenses for diagnosed diabetes in Arizona were estimated at $5.1 billion.

The proven benefits of lifestyle changes through diet, exercise, physical activity, and behavior modification are well documented yet critically underutilized for the management of T2DM and obesity. While implementation and patient compliance are primary barriers, behavioral interventions can minimize cost, improve quality of care, and enhance patient outcomes. Obesity, or being overweight, remains the number one risk factor for T2DM. In addition to lifestyle changes, there are now five FDA-approved anti-obesity drug classes and clinical practice guidelines that present evidence for their use, although barriers continue to exist in the prescription of these pharmacotherapies.

Cardiovascular disease is the leading cause of death in Arizona and the US. The link between cardiovascular, renal, and metabolic diseases in patients with T2DM is common, with an estimated 51% having ≥3 related cardio-renal-metabolic conditions. New approaches to the management of T2DM that address both glycemia and overlapping comorbidities can protect patients against heart and renal failure.

There is now a vast selection of drug classes, pharmacotherapies, and devices from which to choose when developing individualized treatment plans for patients with T2DM. Added to this armamentarium are new formulations and combinations of existing drugs. To continually improve T2DM management in practice, it is imperative that clinicians remain current on newly released clinical practice guidelines, recent treatment advances, updated indications, and the mechanisms of action for newer pharmacotherapies that offer innovative options to fine-tune treatment regimens, improve glucose control, and help patients meet their treatment goals.

Clinicians often lack knowledge of proper risk adjustment factor (RAF) scoring and which diabetes-related services, such as medical nutrition therapy and self-management education, are reimbursable through Medicare and private insurance. Recent changes in reimbursement policies stand to increase access to these services. In addition to office visits, diabetes supplies and medications, adjunct diabetes-related services are highly beneficial and should be considered as part of the care plan.

The 8th Annual Southwest Diabetes Symposium will present current information and evidence-based strategies on these topics. Clinicians will assess case studies using an interactive audience response system to increase knowledge, improve competence, and help facilitate change in performance and professional practice.

CME Accreditation and Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of St. Joseph’s Hospital and Medical Center, and MandatoryCE. St. Joseph’s Hospital and Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

St. Joseph’s Hospital and Medical Center designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP CME Credit 
This Live activity, 8th Annual Southwest Diabetes Symposium, from 03/16/2019 - 10/05/2019, has been reviewed and is acceptable for up to 5.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit 
This continuing nursing education activity was approved by the Continuing Nursing Education Group, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. (5.0 Contact Hours)

CDR Credit
This activity has been approved by the Commission on Dietetic Registration for 5.0 CPEUs.

ACPE CPE Credit 
The Arizona Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been approved for up to 5.0 contact hours (0.50 CEUs) of continuing pharmacy education credit by the Arizona Pharmacy Association, an ACPE-approved provider.

 

Register today for this complimentary symposium by selecting a date/city from the drop down list below, or call 888-YourCE1 (888-968-7231).

 

Faculty Bios and Disclosures

Roberto Ruiz, MD, FACP
Dr. Ruiz is a Doctor of Internal Medicine, as well as a Board Certified Internal Medicine Specialist. He is Diplomat of the American Board of Internal Medicine and also a Fellow of the American College of Physicians. He operates his own practice; the Southwest Internal Medicine Group in Phoenix, Arizona. Dr. Ruiz has been awarded recognition the past three years by the National Committee for Quality Assurance NCQA, Diabetes Physician Recognition Program DPRP. He has also been awarded for the past three years by the National Committee for Quality Assurance NCQA, and the American Heart Association/American Stroke Association by the Heart/Stroke Recognition Program HSRP. Since July 2008 his practice has been awarded recognition as an accredited Echocardiography Laboratory by the Intersocietal Accreditation Commission (IAC).

He received his Doctor of Medicine at the Autonomous University of Guadalajara, Jalisco, Mexico 1975 to 1979 and did his Internship and Residency at Catholic Medical Center of Brooklyn, affiliated with Cornell Medical School. He has over 30 years professional experience as a Physician and is Executive Director of the Arizona Diabetes Foundation, DBA Southwest Diabetes and Obesity Consortium since 2007. He is presently an Adjunct Assistant Professor, Clinical Division, Midwestern University Arizona College of Osteopathic Medicine and serves on the Advisory Board of the College of Nursing, Grand Canyon University since 2005. In 2010 Dr. Ruiz accepted the position of Assistant Clinical Professor of Medicine for University of Arizona, College of Medicine-Phoenix Campus. In 2012, Dr. Ruiz accepted the position of Assistant Clinical Professor of Medicine at University of Creighton College of Medicine, Phoenix Campus.

Disclosure: Roberto Ruiz, MD, FACP
Speakers Bureau: Janssen, Kowa, Merck
Consultant: Novo Nordisk, AstraZeneca

 

Philip Levy, MD, MACE
Dr. Levy is a Clinical Professor of Medicine at the University of Arizona College of Medicine, and was past Chairman of the Section of Endocrinology and Metabolism at Banner University Medical Center in Phoenix, Arizona, as well as past Chief of Staff and past Chairman of Medicine. He is a practicing Endocrinologist with the Banner University Medical Group. He had practiced Clinical Endocrinology at Phoenix Endocrinology Clinic, LTD in Phoenix for more than 40 years. Dr. Levy graduated from the University of Pittsburgh School of Medicine in Pittsburgh, PA. He completed his Internship, Internal Medicine Residency, and Fellowship in Metabolism and Endocrinology at Michael Reese Hospital and Medical Center in Chicago, Illinois. Dr. Levy was a Research Fellow in Endocrinology at Guy’s Hospital Medical Center in London, England.

Dr. Levy served on the American Association of Clinical Endocrinologists (AACE) Board of Directors for six years, is past President of the American College of Endocrinology and was Editor-in-Chief of The First Messenger. He is past President and Founding Member of the Board of Directors of the Arizona Diabetes Association (ADA). Dr. Levy is an active member of AACE, American Medical Association and ADA in numerous capacities. He is a past member of The American Diabetes Association Board of Directors. He was also an Arizona Division of Motor Vehicles Medical Advisory Board Member, member of the Arizona Blue Shield, The Endocrine Society, American College of Physicians, Society of Nuclear Medicine, Arizona Medical Association, Clinical Endocrinology Editorial Board, and Endocrine Today Editorial Board. Dr. Levy is former Diabetes Forecast Editor-in-Chief and Clinical Diabetes Editorial Board Member. He is a past Editorial Board Member of Endocrine Practice. He is also a life member of the National Registry of Who’s Who. He is a Senior Editor of Endocrinology, Diabetes and Metabolism Case Reports.

Dr. Levy was presented the AACE Yank D. Coble, Jr., M.D., Distinguished Service Award in 2000 and the Master of the American College of Endocrinology Award in 2008. He recently was honored by the Arizona Chapter of AACE for his outstanding contributions to Endocrinology.

Disclosure: Philip Levy, MD, MACE
Honorarium and Speaker's Bureau: Janssen
Consultant: Sanofi, Novo Nordisk

 

W. Timothy Garvey, MD, FACE
Dr. Garvey is the Butterworth Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He obtained his MD degree from St. Louis University, completed residency training in Internal Medicine at Barnes Hospital, Washington University, and was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at UAB, University of California San Diego School of Medicine, Indiana University School of Medicine, and Medical University of South Carolina where he directed the Endocrinology Division.

Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans. The Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance and has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray, e.g., NR4A orphan nuclear receptors and the tribbles gene family, and has elucidated the role of adiponectin in cardiometabolic disease. He has contributed to the training of clinicians, basic scientists, and physician scientists. Since 1987, his laboratory has been supported by the NIH, Department of Veterans Affairs, AHA, JDFI, ADA, and other agencies.

Dr. Garvey’s career has been distinguished by a second impactful sphere of activity involving our understanding of obesity as a disease, and in advancing medical models to improve the care of patients with obesity. Dr. Garvey was the chief architect of the Complications-Centric Model for Care of the Overweight/Obese Patient. Much of his work in this area has occurred as a board member in the American Association of Clinical Endocrinologists and chair of the AACE Obesity Committee. Dr. Garvey was a lead author in the AACE Position Statement designating Obesity as a disease (Endocrine Practice 18:642, 2012); chair of the AACE Obesity Consensus Conference held in Washington DC in 2014; lead author on the evidence-based AACE obesity management guidelines (Endocr Pract. 22(7):842, 2016); and co-author of the new medical diagnostic term for obesity – Adiposity-Based Chronic Disease. This obesity treatment algorithm emphasizes the use of weight loss therapy to treat obesity-related complications as the primary goal of treatment, as opposed to reductions in BMI per se. Further, Dr. Garvey developed Cardiometabolic Disease Staging (Obesity 22:110, 2014) that allows clinicians to quantify risk for Type 2 Diabetes and cardiovascular disease mortality, when deciding upon the intensity of weight loss therapy for their patients. Thus, Dr. Garvey is a national leader in medical models for the management of obesity and diabetes prevention.

Disclosure: W. Timothy Garvey, MD, FACE
Consultant: BOYDSense, American Medical Group Association, Novo Nordisk, Merck, Gilead, AMGEN, Sanofi, Elevian
Grant/Research Support: Merck, Sanofi, Pfizer, Novo Nordisk
Major Stockholder: ISIS, Pfizer, Lilly, Novartis, Bristol-Myers Squibb, Merck

 

Pablo Mora, MD, MSc, FACE, CDE
Dr. Mora completed his undergraduate and graduate medical education at the University of Costa Rica School of Medicine. He completed postgraduate studies in internal medicine at the University of Costa Rica and University Hospitals in San Jose, Costa Rica where he also completed a critical care fellowship. He then went on to complete a fellowship in endocrinology and metabolism at the University of Texas Southwestern Medical Center in Dallas, Texas.

After graduation, Dr. Mora worked as Internal Medicine Staff at Parkland Memorial Hospital in Dallas and in 2001, joined the University of Texas Southwestern Medical School faculty, where he remained until 2012 with the rank of Associate Professor of Medicine. He accepted a position as staff Endocrinologist with the Department of Endocrinology of the Cleveland Clinic in Weston, Florida until June 2013.

Currently, he is a practicing Endocrinologist with Dallas Diabetes Research Center at Medical City Dallas and holds an appointment as Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas, Texas.

Dr. Mora is a Certified Diabetes Educator and a fellow of the American College of Clinical Endocrinologists. His clinical interests include diabetes in special populations, post-transplantation diabetes, and modern insulin therapy.

Disclosure: Pablo Mora, MD, MSc, FACE, CDE
Honorarium/Expenses: Novo Nordisk
Consultant: Novo Nordisk, Merck
Speaker’s Bureau: Novo Nordisk, Merck, AstraZeneca, Janssen

 

Krishnaswami Vijayaraghavan, MD, MS, FACC, FACP, FNLA, FHFSA
Dr. Vijay is the Medical Director of the Institute of Congestive Heart Failure at Abrazo Arizona Heart Institute and Hospital in Phoenix. He is a Non-invasive Cardiologist, a trained endocrinologist, clinical lipidologist, an ardent researcher and a Heart Failure specialist. He also holds a Master of Science degree in Clinical Research Design and Statistical Analysis from the University of Michigan.

He has been in clinical practice in Arizona for more than 27 years. Dr. Vijay is a past Governor of the American College of Cardiology, Arizona Chapter, Past President of the National Lipid Association, South West Chapter, current Executive Council Chair of National Lipid Association, a founding member and past President of the Cardio Renal Society of America and current President of the TWINEPIDEMIC, Inc., a nonprofit organization addressing Diabetes and Heart disease among Ethnic Communities all over the world. He is a Fellow of the American College of Cardiology, the American College of Physicians, National Lipid association and Heart Failure Society of America. He is a member of the clinical cardiology council as well as council for Atherosclerosis, Thrombosis and Vascular Biology at American Heart Association, a member of Prevention and Cardio-metabolic committee at American College of Cardiology and an Executive Board member of the National Lipid Association.

Dr. Vijay has participated in more than 180 clinical trials and his research is focused on such disorders as congestive heart failure, hypercholesterolemia, hypertension, coronary artery disease, plaque regression, Atrial Fibrillation, peripheral vascular disease and diabetes/metabolic syndrome. He has published numerous articles in peer reviewed journals. Dr. Vijay serves as a Clinical Professor of Medicine at University of Arizona, Phoenix and as an adjunct Professor of Medicine at Midwestern University Arizona College of Osteopathic Medicine (AZCOM).

Dr. Vijay is a founding member of the Arizona Managed Care Quality Enhancement Program (AMCQEP), 1992, and received the Governor’s award from Health Services Advisory Group (HSAG), October 2002, an innovation award through the Center for Health Innovation and Clinical Trial (CHI&CT) at Arizona State University from the President of Arizona State University in 2010 and the Jerome Markowitz award for a distinguished career from South Asian Society of Atherosclerosis and Thrombosis in 2013. He was one of the three nominees of Healthcare Heroes award for Phoenix Business Journal towards Life time achievement in 2017.He received a Lifetime achievement award from American College of Cardiology, Arizona Chapter in 2018.

He has presented at numerous national and International meetings on diabetes and heart disease. His professional activities also include serving on Editorial Boards of medical journals, reviewing and contributing towards landmark guidelines and policy statements as well as serving on many important advisory boards dealing with Quality initiatives of national organizations.

Disclosure: Krishnaswami Vijayaraghavan, MD, MS, FACC, FACP, FNLA, FHFSA
Honorarium/Expenses: Novartis, Amgen, AstraZeneca, Novo Nordisk, Boehringer Ingelheim
Advisory Board: Boehringer Ingelheim, Amgen, AstraZeneca

 

Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE
Virginia Valentine practices as a Diabetes Specialist with Clinica La Esperanza in Albuquerque managing a wide variety of clinical challenges in diabetes in a primary care group. She is also a volunteer clinician with Endo Echo with University of New Mexico. Project ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management that empowers clinicians across New Mexico to provide better care to more people, right where they live. Ms. Valentine received her Master of Science in Nursing degree from the University of Oklahoma College of Nursing in Oklahoma City. She is board-certified in Advanced Diabetes Management and is a Certified Diabetes Educator.

In 2006, the American Association of Diabetes Educators recognized Ms. Valentine with its Distinguished Service Award and awarded her Fellow status in 2010. In addition to providing clinical management in a primary care practice, Ms. Valentine is a member of the Advanced Practice Advisory Board for the New Mexico Board of Nursing, served on editorial board for Clinical Diabetes, an American Diabetes Association Journal and is a member of international advisory editorial board for Canadian Diabetes Journal. She is on the Advisory Board for Diatribe and US Endocrine. She serves as an advisor to many pharmaceutical and diabetes product companies. Ms. Valentine is the author of the book Diabetes, the New Type 2, a contributor to The Art and Science of Diabetes Self-Management Education Desk Reference 4th edition 2017, as well as articles in various journals including Clinical Diabetes, Diabetes Spectrum, Disease Management, and The Diabetes Educator and Clinical Endocrinology News. She has been living well with type 2 diabetes for over 35 years.

Disclosure: Virginia Valentine, APRN, BC-ADM, CDE, FAADE
Consultant: Abbott, Adocia, AstraZeneca, CapBio, CeQur, Intarcia, Janssen, Lexicon, Lilly, Novo Nordisk, Sanofi, Xeris
Speakers Bureau: AstraZeneca, Lilly, Janssen, Novo Nordisk

 

Mary Ann Hodorowicz, RD, MBA, CDE
Mary Ann Hodorowicz is a nationally recognized registered dietitian/nutritionist, certified diabetes educator and certified endocrinology coder with a MBA degree. She applies nearly forty years of experience in her work as a consultant, writer, speaker and trainer within her business Mary Ann Hodorowicz Consulting, LLC. Mary Ann is known for her expertise in diabetes care, medical nutrition therapy (MNT), diabetes self-management education and support (DSMES), diabetes prevention and related diabetes services. She is especially known for her knowledge on insurance reimbursement, coding and coverage guidelines for these interventions, including remote patient monitoring, chronic care management, continuous glucose management, shared medical appointments and obesity therapy. Her clients are in the health, food, pharmaceutical and insurance industries, and include CMS, the CDC, AADE, and multiple state and local departments of public health. Mary Ann has given over 600 presentations, webinars and live training engagements, at which she generously shares her wide array of practice resources. She has written numerous articles in peer-reviewed journals, authored continuing education online modules for AADE, and is a contributing or lead author for multiple toolkits, fact sheets and ‘how-to’ guides for nutrition and diabetes care professionals on the subjects of insurance reimbursement and creating effective business plans for the sustainability of their services.

Disclosure: Mary Ann Hodorowicz, RD, MBA, CDE
Nothing to disclose.

 

Planning Committee

The following Planning Committee Members have stated they have nothing to disclose: 

Richard Vanderpool, CHCP
Veronica Baez
Kathy Harty
Christine Crowder, MD
Katherine Jorgensen, MSN/MBA, RN-BC, RNC-NIC, Hon.D 

 

Special Needs and ADA Compliance 

Persons with special needs or a disability may request a reasonable accommodation, such as a dietary choices, sign language interpreter, etc., by contacting Richard Vanderpool at 888-YourCE1 (888-968-7231) or richard@mandatoryce.com. Requests should be made as early as possible to allow time to arrange the accommodation.

 

Register today for this complimentary symposium by selecting a date/city from the drop down list below, or call 888-YourCE1 (888-968-7231).